Abstract: This invention describes a cross-sectional study that examines the trends of long-term complications, particularly the incidence of type 2 diabetes mellitus (T2D), in the Saudi population following SARS-COV-2 infection and vaccination. The study collected blood samples from 203 healthy blood donors and analyzed various parameters, including HbA1c, liver function tests, kidney function tests, and lipid profiles. The results showed a significant increase in HbA1c, urea, creatinine, alkaline phosphatase, lactate dehydrogenase, and triglycerides among diabetic patients compared to non-diabetic individuals. Notably, individuals with blood group O had the highest incidence of T2D. These findings suggest that SARS-COV-2 infection and vaccination are associated with the worsening of T2D symptoms and highlight the need for large-scale studies to understand the long-term metabolic complications of the COVID-19 pandemic, aiming to develop effective prevention and management strategies.

Abstract: The present invention relates to a method for assessing Atenolol with precision. A pharmaceutical composition comprising: a predefined amount of Atenolol or pharmaceutically acceptable salts thereof; and a combination of pharmaceutical excipients suitable for oral administration, wherein the method for tailoring the treatment of hypertension comprises of determining the levels of C-reactive protein, blood pressure, blood urea, and HbA1c in hypertensive patients; stratifying patients into distinct subgroups based on the identified biomarker levels; and customizing antihypertensive treatment plans for each subgroup, wherein treatment may include, but is not limited to, beta blockers such as Atenolol.